Down-regulation of miR-9* in the peripheral leukocytes of Huntington’s disease patients

Table 2 miRNA levels in the peripheral leukocytes from patients with Huntington’s disease versus healthy controls

miRNA	HD (n = 36)	PreHD (n = 8)	Normal control (n = 28)	P value^‡
miR-9^*	0.0008 ± 0.0013^*	0.0008 ± 0.0011	0.0028 ± 0.0035	0.005
miR-9	0.0019 ± 0.0019	0.0007 ± 0.0008	0.0037 ± 0.0055	0.064
miR-1	0.0013 ± 0.0015	0.0018 ± 0.0022	0.0029 ± 0.0035	0.070
miR-330	0.0128 ± 0.0081	0.0208 ± 0.0157	0.0184 ± 0.0098	0.071
miR-29b	0.0023 ± 0.0043	0.0055 ± 0.0061	0.0038 ± 0.0039	0.075
miR-10b	0.0013 ± 0.0012	0.0024 ± 0.0029	0.0022 ± 0.0019	0.092
miR-615	0.0238 ± 0.0370	0.0080 ± 0.0074	0.0336 ± 0.0328	0.212
miR-196a	0.0072 ± 0.0063	0.0136 ± 0.0143	0.0122 ± 0.0139	0.252
miR-196b	0.0089 ± 0.0093	0.0146 ± 0.0156	0.0161 ± 0.0213	0.265
miR-155	0.0684 ± 0.0505	0.0928 ± 0.0765	0.0639 ± 0.0464	0.448
miR-132	0.0381 ± 0.0255	0.0476 ± 0.0346	0.0457 ± 0.0354	0.661
miR-29a	0.0926 ± 0.1003	0.1024 ± 0.0911	0.1136 ± 0.1368	0.841
miR-124a	Not detectable	Not detectable	Not detectable

HD Huntington’s Disease, PreHD pre-sympatomatic Huntington’s disease
^‡ P value of ANCOVA with adjustment of age and gender
^*Statistically significant in comparison with healthy controls, P < 0.05, ANCOVA with adjustment of age and gender

ISSN: 1750-1172